注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Jasper Therapeutics Inc 是一家專註於造血細胞移植療法的生物技術公司。該公司已經開發了一些項目,如JSP191,一種正在進行臨床開發的抗CD117的單克隆抗體,作為一種調節劑,清除接受造血細胞移植的患者骨髓中的造血幹細胞。它旨在實現治療性異體和自體造血細胞移植和基因療法。該公司還提供一個臨床前工程造血幹細胞(eHSC)平臺,旨在克服異體和自體基因編輯幹細胞移植的局限性。該項目用於治療和擴大造血幹細胞療法,以治愈威脅生命的癌癥、地中海貧血癥、鐮狀細胞疾病、遺傳性疾病和自身免疫性疾病患者。JSP191在移植前清除骨髓中的造血幹細胞。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Kurt von Emster | 55 | 2019 | Independent Director |
Christian W. Nolet | 65 | 2021 | Independent Director |
Ronald A. Martell | 61 | 2022 | President, CEO & Director |
Frederick R. Appelbaum | - | - | Member of Scientific Advisory Board |
Harry Malech | - | - | Member of Scientific Advisory Board |
Vishal Kapoor | 47 | 2023 | Independent Director |
Daniel C. Adelman | 66 | 2023 | Member of Scientific Advisory Board & Senior Clinical Advisor |
Anna Louise French | 35 | 2019 | Independent Director |
Arthur Weiss | - | - | Member of Scientific Advisory Board |
Jeffrey V. Ravetch | 72 | - | Member of Scientific Advisory Board |
Stephen J. Galli | 76 | 2023 | Member of Scientific Advisory Board |
Judith Anne Shizuru | 67 | 2018 | Co-Founder & Director |
Scott C. Brun | 55 | 2023 | Independent Director |
Thomas G. Wiggans | 72 | 2023 | Independent Chairman |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核